Abintus Bio, Inc

Driven by a bold founding vision: Empowering patients from within, Abintus is pioneering potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patients body, also termed in vivo. These therapies are based on Abintus clinically proven Modular Delivery Platform (MDP). The companys two initial, fit-for-purpose, In Vivo programs are: 1. Highly selective gene expression targeting cell type/state via synthetic biology (e.g., In Vivo CAR-NK/T/Treg, In Vivo TCR-T) with applications across multiple gene delivery systems (e.g., AAV, lenti, adeno, retro) and therapeutic areas including leukemia, solid tumors, autoimmune, infectious, and genetic disease. 2. Simultaneous engineering of a diverse repertoire...

Gene therapy,viral manufacturing,viral engineering,in vivo gene therapy,and in vivo cart

Abintus bio, inc operates in the Biotechnology industry.

Abintus bio, inc's revenue is 11m - 100m

Abintus bio, inc has 11 - 50 employees.